1.Correlations of serum TgAb and TPOAb and clinicopathological features of PTC in children and adolescents
Dongmei HUANG ; Jingtai ZHI ; Jinming ZHANG ; Xiangqian ZHENG ; Jingzhu ZHAO ; Songfeng WEI ; Ming GAO
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2022;57(12):1418-1425
		                        		
		                        			
		                        			Objective:To analyze the correlations between serum thyroglobulin antibody (TgAb) and thyroid peroxidase antibody (TPOAb) and clinicopathological features in children and adolescents with papillary thyroid carcinoma (PTC).Methods:A retrospective analysis was conduced on the clinicopathological data of children and adolescents (age≤21 years old) with PTC admitted to Tianjin Medical University Cancer Hospital from 2011 to 2019, and then, we used χ 2 test or Fisher′s exact probability test to compare the differences in clinicopathological characteristics between groups with different TgAb and TPOAb status and multivariate logistic regression model analysis to evaluate independent predictors of cervical lymph node metastasis. Results:A total of 304 patients, including 89 males and 215 females, aged 5-21 years (median age 19 years), were enrolled in this study. The comparison between groups with different TgAb and TPOAb status showed that there were significant differences in gender, preoperative thyroglobulin (Tg) level, primary tumor location, number of primary tumors and maximum tumor diameter (all P<0.05), which suggested that TgAb +group ( n=81) and TPOAb +group ( n=84) had relatively better primary tumor characteristics. Patitents with TgAb +and TPOAb +were more common in females and their preoperative Tg level was mostly within the normal range, and there were significant differences in primary tumor location, number of primary tumors and maximum tumor diameter between TgAb +and TgAb -(223 cases) groups (all P<0.05). There was significant difference in the maximum tumor diameter between TPOAb +and TPOAb -(220 cases) groups ( P<0.05). Analysis of risk factors for cervical lymph node metastasis showed that independent risk factors for central lymph node metastasis were maximum tumor diameter>2 cm ( OR=2.84, 95% CI: 1.59-5.07, P<0.001) and extra-thyroid extension ( OR=0.32, 95% CI: 0.17-0.60, P<0.001), and independent risk factors for lateral neck lymph node metastasis included age≤14 years old ( OR=0.34, 95% CI: 0.18-0.67, P=0.002), preoperative Tg +( OR=2.16, 95% CI: 1.10-4.24, P=0.026) and maximum tumor diameter>2 cm ( OR=3.99, 95% CI: 2.33-6.82, P<0.001). Conclusion:It is recommended to test routinely serum TgAb and TPOAb before surgery in children and adolescents with PTC. Preoperative Tg +, age≤14 years, maximum tumor diameter>2 cm, and extra-thyroid extension are risk factors for cervical lymph node metastasis.
		                        		
		                        		
		                        		
		                        	
2.Comparison of the clinicopathological characteristics between mixed medullary and papillary thyroid carcinoma and medullary thyroid carcinoma coexistent with papillary thyroid carcinoma
Songfeng WEI ; Pingping WANG ; Runfen CHENG ; Jingzhu ZHAO ; Yi PAN ; Xiangqian ZHENG ; Yigong LI ; Yang YU ; Ming GAO
Chinese Journal of General Surgery 2021;36(6):405-409
		                        		
		                        			
		                        			Objective:To investigate the difference of clinicopathological characteristics between mixed medullary and papillary carcinoma of thyroid and medullary carcinoma coexistent with papillary carcinoma.Method:The clinicopathological data of 3 MMPTC cases and 9 MTC-PTC cases treated at Tianjin Medical University Cancer Institute & Hospital during the past ten years were retrospectively analyzed. The differences in clinical characteristics, pathological characteristics, immunohistochemistry results, treatment and prognosis of the two groups were compared.Results:In the MMPTC group, the median onset-age was 59 years old. 3 patients were all medullary carcinoma colliding with micropapillary carcinoma. The immunohistochemistry results showed that medullary carcinoma and papillary carcinoma showed their distinctive immunohistochemical characteristics. The lymph node metastasis rate was 66.7% (2/3). In MTC-PTC group, the median onset-age was 55; 8 out of 9 patients had an increased preoperative calcitonin level. Medullary carcinoma and papillary carcinoma showed their distinctive immunohistochemical characteristics. Four out of the 9 cases had lymph node metastasis.Conclusion:Compared with MTC-PTC, MMPTC is more common in middle-aged and elder patients, with higher lymph node metastasis rate. The pathogenesis of MTC-PTC is similar to papillary thyroid carcinoma, and the treatment should be individualized. The prognosis of these two groups of patients is fair.
		                        		
		                        		
		                        		
		                        	
3.Correlation between BRAF mutation and clinicopathological characteristics in pediatric papillary thyroid carcinoma
Jingzhu ZHAO ; Xiangqian ZHENG ; Ming GAO ; Jiadong CHI ; Xinwei YUN ; Songfeng WEI ; Yigong LI
Chinese Journal of Applied Clinical Pediatrics 2021;36(3):182-185
		                        		
		                        			
		                        			Objective:To investigate the BRAF(V600E)gene mutation of pediatric papillary thyroid carcinoma (PTC) and refine their clinicopathological correlates. Methods:Tumor tissue samples of pediatric PTCs (≤18 years old) were collected from tumor tissue bank of Tianjin Medical University Cancer Institute and Hospital from January 2012 to December 2016.The medical records of 22 patients with pediatric PTC were reviewed retrospectively.The frequencies of BRAF(V600E) mutation were evaluated and the correlation between BRAF(V600E) mutation and clinical characteristics were analyzed. Results:BRAF(V600E) mutations were present in 45.5% of cases (10 cases). BRAF(V600E) mutation in pediatric PTC was obviously lower than that in adults PTC(77.7%) ( χ2=11.250, P=0.001). BRAF(V600E) mutation in>12-year-old group (66.7%) was remarkably higher than that in ≤12-year-old group (20.0%) ( P<0.05). BRAF(V600E) mutation in female (69.2%) was greatly higher than that in male (11.1%) ( P<0.05). There was no significant correlation with BRAF(V600E) mutation and multiple tumor, tumor size, highly invasive subtype, extrathyroidal extension, lymph node metastasis and radiological history of infants (all P>0.05). The median follow-up time was 45 months.No patients died and BRAF(V600E) mutation was not associated with the increase of recurrence rate ( P>0.05). Conclusions:BRAF(V600E)gene mutation in pediatric PTC is lower than that in adults. BRAF(V600E) mutation does not portend a more aggressive clinical biological behavior in pediatric PTC.
		                        		
		                        		
		                        		
		                        	
4.The role of thyroglobulin in diagnosis of lateral cervical lymph node recurrence in papillary thyroid cancer after radioiodione therapy
Jingzhu ZHAO ; Pingping WANG ; Ming GAO ; Xiangqian ZHENG ; Xinwei YUN ; Songfeng WEI ; Dapeng LI ; Jiadong CHI
Chinese Journal of General Surgery 2021;36(3):204-207
		                        		
		                        			
		                        			Objective:To evaluate the role of Tg in diagnosis of lateral cervical lymph node recurrence in papillary thyoid cancer(PTC)after radioactive iodine(RAI) therapy.Methods:From Jan 2012 to Aug 2018, 22 PTC patients who received RAI therapy after operation were reoperated for lateral cervical lymph node recurrence. The clinical data was retrospectively analyzed.Results:The median recurrence time was 30.5 (5-86) months. All 22 patients received RAI therapy after the first operation, and the median dose of RAI was 250mCi(100-700 mCi) and the episode of RAI therapy ranged from 1 to 4. All 22 PTC patients underwent neck reoperation, among which 20 cases were identified to have lymph node metastasis. The median number of lymph nodes dissected was 31 (8-83) and median number of metastatic lymph nodes was 4 (1-19) . The diagnostic accuracy of ultrasonography in detecting lymph node metastasis was 90.9%. Before reoperation, the median Tg was 1.305 (0.10-99.51) μg/L, with the cutoff value of Tg being 0.2 μg/L, and its sensitivity and specificity were 80.0% and 100%, respectively. The median stimulated Tg was 5.89 (0.14-255.80) μg/L in the 10 patients, with the cutoff value of stimulated Tg of 2 μg/L, and its sensitivity and specificity were 88.9% and 100%, respectively.Conclusions:The serum Tg level is helpful for monitoring the recurence of PTC, but recurrence cannot be completely ruled out for those with low Tg.
		                        		
		                        		
		                        		
		                        	
5.Analysis of gene mutation profile of adult soft tissue sarcomas using high-throughput sequencing technology
Songfeng XU ; Wenwei WANG ; Jun CHEN ; Ting LIU ; Xinxin ZHANG ; Libin XU ; Zhenguo ZHAO ; Shengji YU ; Lixia GUO
Chinese Journal of Oncology 2020;42(9):741-745
		                        		
		                        			
		                        			Objective:To understand the genetic variation of soft tissue sarcomas, and to provide a scientific evidence for the individualized treatment.Methods:The somatic mutation and germline mutation of 45 adult soft tissue sarcomas had been detected by high-throughput sequencing technology, the clinical data were also analyzed.Results:A total of 88 gene mutations were detected in 45 samples, including 78 single nucleotide variation (SNV), 13 insertion/deletion (Indel) and 19 copy number variation (CNV). The most common mutant genes are TP53, CDKN2A, MDM2, CDK4, NF1 and PTEN. Among them, the mutation rates of TP53-MDM2/MDM4-CDKN2A pathway, CDKN2A/CDK4/RB1 pathway, and RAS/NF1/PTEN/PI3K pathway were more frequent (32/88, 36%). In terms of immunotherapy biomarkers among 10 samples, the median value of tumor mutation burden was 2.02 muts/Mb (0-4.24 muts/Mb), and all were microsatellite stable.Conclusions:This study analyzes the genetic variation of soft tissue sarcoma, and determines the high-frequency gene mutations and pathways, which may be the potential drug targets. This finding can provide scientific evidences for the personalized treatment of soft tissue sarcoma.
		                        		
		                        		
		                        		
		                        	
6.Analysis of gene mutation profile of adult soft tissue sarcomas using high-throughput sequencing technology
Songfeng XU ; Wenwei WANG ; Jun CHEN ; Ting LIU ; Xinxin ZHANG ; Libin XU ; Zhenguo ZHAO ; Shengji YU ; Lixia GUO
Chinese Journal of Oncology 2020;42(9):741-745
		                        		
		                        			
		                        			Objective:To understand the genetic variation of soft tissue sarcomas, and to provide a scientific evidence for the individualized treatment.Methods:The somatic mutation and germline mutation of 45 adult soft tissue sarcomas had been detected by high-throughput sequencing technology, the clinical data were also analyzed.Results:A total of 88 gene mutations were detected in 45 samples, including 78 single nucleotide variation (SNV), 13 insertion/deletion (Indel) and 19 copy number variation (CNV). The most common mutant genes are TP53, CDKN2A, MDM2, CDK4, NF1 and PTEN. Among them, the mutation rates of TP53-MDM2/MDM4-CDKN2A pathway, CDKN2A/CDK4/RB1 pathway, and RAS/NF1/PTEN/PI3K pathway were more frequent (32/88, 36%). In terms of immunotherapy biomarkers among 10 samples, the median value of tumor mutation burden was 2.02 muts/Mb (0-4.24 muts/Mb), and all were microsatellite stable.Conclusions:This study analyzes the genetic variation of soft tissue sarcoma, and determines the high-frequency gene mutations and pathways, which may be the potential drug targets. This finding can provide scientific evidences for the personalized treatment of soft tissue sarcoma.
		                        		
		                        		
		                        		
		                        	
7. Treatment and analysis of prognostic factors of stage Ⅱ and Ⅲ undifferentiated high-grade pleomorphic sarcoma in extremities and trunk
Xinxin ZHANG ; Libin XU ; Songfeng XU ; Zhenguo ZHAO ; Hui FANG ; Peiqing MA ; Ting LIU ; Shuguang ZHANG ; Shengji YU
Chinese Journal of Oncology 2019;41(2):140-145
		                        		
		                        			 Objective:
		                        			To evaluate the efficacy and prognostic factors of comprehensive treatment of undifferentiated high grade pleomorphic sarcoma (UHGPS) in extremities and trunk, including surgery, radiotherapy and chemotherapy.
		                        		
		                        			Methods:
		                        			A retrospective analysis and follow-up of 131 UHGPS cases with clinical stage Ⅱ or Ⅲ in extremities and trunk soft tissue was performed to analyze the prognostic factors. Survival data were collected through follow-up. The survival rate was calculated with life table method and Kaplan-Meier survival curves were drawn. Survival rate between the two groups was compared using Log rank test. The multivariate analysis was performed using Cox regression model.
		                        		
		                        			Results:
		                        			The median survival time of 131 patients was 41.6 months. The 1-year, 3-year and 5-year survival rates were 95.0%, 82.0%, and 77.0%, respectively. The 5-year recurrence-free survival rate was 81.0%, and the 5-year metastasis-free survival rate was 72.0%. Univariate analysis showed that the tumor size, initial or recurrence, surgical margin, AJCC stage, and with/without standard treatment were associated with overall survival (all 
		                        		
		                        	
8.Effects of complete and incomplete resection of the cyst wall for treating adult type Ⅰ choledochal cyst
Huxiao CUI ; Yilei DENG ; Songfeng MENG ; Sen HOU ; Longshuan ZHAO
Chinese Journal of Hepatobiliary Surgery 2019;25(1):40-44
		                        		
		                        			
		                        			Objective To investigate effects of complete resection of the cyst or incomplete resection with 3 ~ 5 mm remnant proximal cyst wall in treating adult type Ⅰ choledochal cyst (CC).Methods Medical records of 133 surgical patients with type Ⅰ CC from December 1995 to December 2017 in the First Affiliated Hospital of Zhengzhou University were reviewed retrospectively.According to whether to reserve the 3 ~ 5 mm cyst wall in proximal end of cyst,133 patients were divided into unreserved group (n =85) and reserved group (n=48),and the related indicators of the two groups were compared and analyzed.Results No significant difference was observed in age,sex ratio,clinical performance between the two groups(all P>0.05).And there was no statistical difference in the operation time,intraoperative blood loss,and biliary-intestinal anastomosis diameter between the two groups(all P>0.05).The main complications of the two groups were similar,including incision and abdominal infection,bile leakage,cholangitis,reflux cholangitis,bile duct stones and anastomotic stricture,and there was no statistical difference in the incidence of each complication.Biliary-intestinal anatomical site malignancy was observed in one patient with recurrent cholangitis in the reserved group in the 33th months.Conclusions There was no statistical difference in the incidence of early and late complications in two different methods of cyst management for treating adult type Ⅰ CC.Whether reserve the 3~5 mm cyst wall in proximal end of CC increases the risk of cancer still needs further studies.
		                        		
		                        		
		                        		
		                        	
9. The role of preoperative 18F-FDG PET-CT in lymphatic metastasis diagnosis of cutaneous malignant melanoma on extremities and trunk
Xinxin ZHANG ; Yan FANG ; Libin XU ; Songfeng XU ; Zhenguo ZHAO ; Chao SUN ; Peiqing MA ; Ting LIU ; Shengji YU ; Wenjie ZHANG
Chinese Journal of Oncology 2018;40(5):372-378
		                        		
		                        			 Objective:
		                        			To evaluate the clinical value of preoperative 18F-Fludeoxyglucose (18F-FDG PET-CT) in lymphatic metastasis diagnosis of cutaneous melanoma on extremities and trunk.
		                        		
		                        			Methods:
		                        			112 patients with cutaneous melanoma pathologically of extremities and trunk from January 2006 to December 2016, who received 18F-FDG PET-CT examination preoperatively, were retrospectively reviewed. The correlations between the maximal diameters of lymph nodes, the maximal standard uptake value (SUV) and the diagnostic impression grades of PET-CT examination, and the final pathological diagnosis were analyzed. The correlations between Breslow thickness of primary lesions and the diagnostic impression of PET-CT examination were also analyzed. All the above were analyzed with Receiver Operating Characteristic (ROC) curve to get the cut-off value. Based on the final results of pathological diagnosis of lymph nodes as the golden standard, the statistically significant indicators of ROC curve analysis were used to evaluate the diagnostic effect, as well as to calculate the sensitivity, specificity and accuracy. With gender, age, maximal diameter of lymph nodes, maximal SUV, diagnosis impressions, and Breslow thickness as the independent variables and pathological diagnosis results of lymph nodes as the dependent variable, two-class stepwise Logistic regression analysis was used to determine the independence of diagnostic indicators. ROC curve analysis and log rank test were used to analyze the relationship between Breslow thickness and patient survival.
		                        		
		                        			Results:
		                        			To evaluate melanoma patients′ lymph node status, the results of ROC curve analysis showed that the area under the curve of lymph node maximal diameter, maximal SUV, diagnosis impression of PET-CT examinations were 0.789, 0.786 and 0.816, respectively (all 
		                        		
		                        	
10. Analysis of clinicopathological characteristics and prognostic factors of foot and ankle soft tissue and bone tumors
Xinxin ZHANG ; Libin XU ; Songfeng XU ; Zhenguo ZHAO ; Ting LIU ; Shuguang ZHANG ; Shengji YU
Chinese Journal of Oncology 2018;40(9):685-689
		                        		
		                        			 Objective:
		                        			To evaluate the clinicopathological characteristics of foot and ankle soft tissue and bone tumor, and to analyze the prognosis and the related factors of malignant tumors in this site.
		                        		
		                        			Methods:
		                        			74 patients with soft tissue and bone tumors of foot and ankle from January 2006 to February 2017 were retrospectively analyzed. The clinicopathological characteristics, the treatment and survival status of malignant tumors were followed up, and the clinical and therapeutic factors related to prognosis were analyzed.
		                        		
		                        			Results:
		                        			Of the 74 patients, 34 were males and 40 were females. The male to female ratio was 1∶1.18; the age ranged from 12 to 64 years and the median age was 42 years. Tumors located in forefoot of 22 cases, 22 in midfoot, 10 in hind foot, 14 in ankle joint and 6 in multiple sites. 14 cases were bone tumors, including 7 benign and 7 malignant, and 60 cases were soft tissue tumors, including 14 benign and 46 malignant. The most common malignant soft tissue tumors were synovial sarcomas (13 cases), and the most common benign soft tissue tumors were hemangiomas (4 cases). 44 cases of malignant tumors underwent surgery were followed up, of which were 7 bone and 37 soft tissue malignant tumors. Limb salvage surgeries were performed in 33 cases and amputation in 11 cases. The median follow-up time was 69.8 months, and the median survival time was 40.7 months. The 1-year, 3-year and 5-year survival rate of soft tissue malignant tumors was 88.0%, 73.0%, and 63.0%, respectively. The 1-year, 3-year and 5-year survival rate of bone malignant tumors was 86.0%, 57.0% and 57.0%, respectively. Univariate analysis showed that the prognostic factors affecting 5-year survival rate were tumor size and adjuvant therapy (
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail